Influence of voriconazole and fluconazole on reconstituted multilayered oesophageal epithelium infected by Candida albicans

Mycoses

Volumn 47, Issue 7, 2004, Pages 330-337

  Bernhardt, J ^a,d   Bernhardt, H ^a   Knoke, M ^a   Ludwig, K ^b,c  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b Clinic of Surgery   (Germany)

^c Klinikum Suedstadt Rostock   (Germany)

^d Klinikum Südstadt Rostock   (Germany)

Author keywords

Candida albicans; Fluconazole; Reconstituted oesophageal tissue; Tissue model; Voriconazole

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; VORICONAZOLE;

ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ESOPHAGITIS; ESOPHAGUS DISEASE; ESOPHAGUS MUCOSA; FUNGAL STRAIN; FUNGAL VIRULENCE; FUNGUS GROWTH; FUNGUS HYPHAE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; REDUCTION; SURFACE PROPERTY;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; CELL LINE, TUMOR; EPITHELIAL CELLS; ESOPHAGITIS; ESOPHAGUS; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; PYRIMIDINES; TRIAZOLES;

CANDIDA; CANDIDA ALBICANS; FUNGI;

EID: 4344683218     PISSN: 09337407     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2004.01004.x     Document Type: Article

References (17)

1. Bernhardt J, Herman D, Sheridan M, Calderone R. Adherence and invasion studies of Candida albicans strains, using in vitro models of esophageal candidiasis. J Infect Dis 2001; 184: 1170-5.
2. Li D, Bernhardt J, Calderone R. Temporal expression of the Candida albicans genes CHK1 and CSSK1, adherence, and morphogenesis in a model of reconstituted human esophageal epithelial candidiasis. Infect Immun 2002; 70: 1558-65.
3. Bernhardt J, Bernhardt H, Knoke M, Zimmermann K. Influence of voriconazole and fluconazole on reconstituted esophageal epithelium infected by Candida albicans. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, 2002, p. 408 (Abstract M-1506).
4. Enache E, Eskandari T, Borja L, Wadsworth E, Hoxter B, Calderone R. Candida albicans adherence to a human oesophageal cell line. Microbiology 1996; 142: 2741-6.
5. Schaller M, Schäfer W, Korting HC, Hube B. Differential expression of secreted aspartyl proteinases in a model of human oral candidosis and in patient samples from the oral cavity. Mol Microbiol 1998; 29: 605-15.
6. Bernhardt H, Zimmermann K, Knoke M. The continuous flow culture as an in vitro model in experimental mycology. Mycoses 1999; 42 (Suppl. 2): 29-32.
7. Zimmermann K, Bernhardt J, Knoke M, Bernhardt H. Influence of voriconazole and fluconazole on Candida albicans in long-time continuous flow culture. Mycoses 2002; 45 (Suppl. 1): 41-46.
8. Espinel-Ingroff A, Boyle K, Sheehan DJ. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia 2001; 150: 101-15.
9. Johnson E, Espinel-Ingroff A, Troke P. Activity of voriconazole (V), itraconazole (I), fluconazole (F) and amphotericin B (A) in vitro against 1575 yeasts from the voriconazole phase III clinical studies. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, 2002, p. 411 (Abstract M-1519).
10. Cuenca-Estrella M, Díaz-Guerra TM, Mellado E, Monzón A, Rodríguez-Tudela JL. Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain. Eur J Clin Microbiol Infect Dis 1999; 18: 432-5.
11. Chandrasekar PH, Manavathu E. Voriconazole. Drugs Today 2001; 37: 135-48.
12. Belanger P, Nast CC, Fratti R, Sanati H, Ghannoum M. Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species. Antimicrob Agents Chemother 1997; 41: 1840-2.
13. Waldrep TW, Keiser P, Ware A, et al. Failure of intermittent caspofungin therapy to treat fluconazole-resistant mucocutaneous Candida despite apparent in vitro susceptibility. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, 2002, p. 393 (Abstract M-891).
14. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999; 12: 40-79.
15. Klepser ME, Malone D, Lewis RE, Ernst EJ, Pfaller MA. Evaluation of voriconazole pharmacodynamics using time-kill methodology. Antimicrob Agents Chemother 2000; 44: 1917-20.
16. Bernhardt H, Bernhardt J, Knoke M. Changes in Candida albicans colonization and morphology under influence of voriconazole. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, 2002, p. 408 (Abstract M-1505).
17. Ally R, Schurmann D, Kreisel W, et al. A randomised, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001; 33: 1447-54.